Abstract
ObjectiveIn this study, we aimed to evaluate the association between the monoclonal antibody infusion, bamlanivimab, and a reduction in 30-day hospitalization and mortality rates in patients with coronavirus disease 2019 (COVID-19) in a rural community setting with various comorbidities.MethodologyA retrospective data analysis was conducted over a 60-day period for patients who visited the Emergency Department of a community hospital. A group of COVID-19-positive patients who received bamlanivimab was compared with another group of COVID-19 patients with similar characteristics, demographics, and disease severity who did not receive the infusion. Data for 30-day hospitalization rates were analyzed using odds ratio for various individual comorbidities. Fisher’s exact test was used to analyze chronic kidney disease (CKD) and mortality. Logistic regression analysis and subsequent odds ratio estimates were used to adjust for demographics and comorbidities and evaluate for the association of bamlanivimab infusion with 30-day hospitalization rates.ResultsA total of 144 patients were included in the bamlanivimab group and 140 patients in the non-bamlanivimab group of COVID-19 patients. When analyzed by comorbidity using odds ratio analysis, 10.3% of diabetic patients, 6.1% of obese patients, 8% of hypertensive patients, and none of the patients with CKD required hospitalization at 30 days from the initial visit in the bamlanivimab group in contrast to 35.2% of diabetic patients, 38.1% of obese patients, 33.9% of hypertensive patients, and 63.6% of patients with CKD in the non-bamlanivimab group. Logistic regression analysis with odds ratio estimates showed that when adjusted for demographics and various comorbidities, bamlanivimab infusion was associated with decreased hospitalization (p < 0.001; confidence interval [CI] = 0.017-0.135). However, using logistic regression and taking all variables into account, among the evaluated comorbidities, only hypertension was found to be individually associated with decreased hospitalization (p = 0.0174; CI = 0.140-0.827) along with younger age (p = 0.0023; CI = 1.017-1.080) and female gender (p = 0.0077; CI = 0.212-0.789). We could not establish mortality benefit in the subgroups.ConclusionsBased on the results of this study, there is an association between bamlanivimab use and reduced hospitalization rates in COVID-19 patients.
Highlights
In December 2019, a new coronavirus was identified after cases of viral pneumonia emerged in the Hubei province of China
A total of 144 patients were included in the bamlanivimab group and 140 patients in the non-bamlanivimab group of COVID-19 patients
Logistic regression analysis with odds ratio estimates showed that when adjusted for demographics and various comorbidities, bamlanivimab infusion was associated with decreased hospitalization (p < 0.001; confidence interval [CI] = 0.017-0.135)
Summary
In December 2019, a new coronavirus was identified after cases of viral pneumonia emerged in the Hubei province of China. The virus was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the disease it causes was named novel coronavirus disease 2019 (COVID-19) [1]. COVID-19 affects different populations in varying severity and is thought to be related to individual response as well as demographics and comorbidities [2]. In October 2020, the investigational neutralizing IgG1 monoclonal antibody bamlanivimab (LY-CoV555; Lilly) was granted EUA for use in mild-to-moderate COVID-19 patients with select demographics and risk factors in the outpatient or emergency department setting as a single one-time intravenous infusion [3]. The BLAZE-1 trial supported the use of bamlanivimab and showed a significant reduction in viral load in patients after 11 days compared to placebo [4]. The EUA comes with the rationale that bamlanivimab may reduce COVID-19-related hospital
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
